SunMed, a North American manufacturer and distributor of consumable medical devices for anesthesia and respiratory care, today announced it has entered into a definitive agreement with Avanos Medical, under which SunMed will acquire Avanos’ respiratory health business, including the BALLARD, MICROCUFF and endOclear product lines.
This combination further expands the breadth of SunMed’s product offering, providing customers with a one-stop source for the most trusted and highest-quality brands in anesthesia and respiratory care, which support the best outcomes for patients.
Through the transaction, SunMed is adding brands to its expansive and growing portfolio, providing healthcare providers and patients with even more options. The BALLARD, MICROCUFF and endOclear brands include closed suction catheters, endotracheal tubes and oral care solutions, whose products have achieved strong trust, recognition and respect among healthcare providers around the world for their high quality and advanced technology. Included in the transaction, in addition to expanding its product lines with these respiratory consumables, SunMed is acquiring two Avanos manufacturing facilities in Mexico and R&D expertise that support these brands.
“Adding these complementary brands into our growing portfolio solidifies SunMed’s leadership as the premier manufacturer of the anesthesia and respiratory consumables that define product excellence and serve patients across the continuum of care,” said Hank Struik, CEO of SunMed. “These products are the standard bearers of closed suction and endotracheal consumables and we deeply admire the clinical results that these exceptional products provide for patients in critical care and the trust they have built with practitioners. Leveraging the expertise behind these successful brands, this transaction also supports our ability to drive growth and innovation, not just for the respiratory brands we are acquiring, but for our comprehensive breathing care platform. Combined with our expansive anesthesia and respiratory consumables business, we are further strengthening SunMed’s ability to serve more clinicians around the world so they can provide the best patient outcomes.”
The proposed transaction, which is subject to customary closing conditions, is expected to be completed by late 2023.
